On October 16, 2018 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) reported that the Company earned $15 million in milestone payments from Pfizer Inc (Press release, BioMarin, OCT 16, 2018, View Source [SID1234529934]). These milestone payments were triggered by the U.S. Food and Drug Administration (FDA) approval of Talzenna (talazoparib) for the treatment of adult patients with deleterious or suspected deleterious germline BRCA (gBRCA)-mutated, HER2-negative locally advanced (LA) or metastatic breast cancer (MBC). Patients are selected for therapy based on an FDA-approved companion diagnostic. These milestone payments are part of an agreement made with Medivation, Inc. when Medivation purchased talazoparib. Medivation was acquired by Pfizer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In August 2015, Medivation, Inc. and BioMarin Pharmaceutical Inc. entered into an asset purchase agreement under which Medivation acquired all worldwide rights to Talzenna (talazoparib), a once-daily, oral poly ADP ribose polymerase (PARP) inhibitor. Under the agreement, Medivation, acquired by Pfizer, is responsible for all research, development, regulatory and commercialization activities for all indications on a global basis.

Under the terms of the agreement, Medivation paid BioMarin $410 million upfront, and BioMarin was entitled to receive up to an additional $160 million (in aggregate) upon the achievement of regulatory and sales-based milestones, of which $35 million has been earned to date, as well as mid-single digit royalties for Talzenna (talazoparib). In June of this year, the European Medicines Agency accepted the Marketing Application for talazoparib for this patient population and is currently reviewing the application.